GXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GXO is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act immediately. The stock has a constructive long-term uptrend, but the near-term setup is mixed: price is near pivot resistance, MACD is still negative, and earnings are only days away. The best direct call from this data is hold rather than buy now. If forced to choose today, the stock is acceptable to monitor but not strong enough to commit a large new position immediately.
GXO is in a bullish medium-term structure because SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which supports an upward trend. However, momentum is not fully confirmed: MACD histogram is -0.0292 and still below zero, though it is improving. RSI_6 at 54.429 is neutral, showing neither overbought nor oversold conditions. Current pre-market price is 57.13, very close to the pivot at 57.355, with upside resistance at R1 59.523 and R2 60.862, while support sits at 55.187 and 53.848. Overall, the trend is positive but not strong enough to call an immediate breakout buy.
["Revenue in Q4 2025 grew 7.91% YoY, showing continued top-line expansion.", "Analyst sentiment has been broadly constructive recently, with multiple price target raises from Citi, JPMorgan, Stifel, Oppenheimer, Susquehanna, UBS, Wells Fargo, and Morgan Stanley.", "Hedge funds are buying, with buying amount up 140.20% over the last quarter.", "Bullish moving-average structure suggests the stock remains in an established uptrend.", "Upcoming earnings on 2026-05-05 could act as a positive catalyst if results and guidance exceed expectations."]
["Goldman Sachs downgraded GXO to Neutral from Buy on 2026-03-04, reducing near-term confidence.", "Net income fell 57.00% YoY in the latest quarter, and EPS declined 55.42% YoY.", "Gross margin also compressed, down to 12.12 from the prior year level.", "MACD remains negative, so momentum is not fully confirmed.", "The stock is near pivot resistance, limiting immediate upside from current levels.", "No recent insider buying support and no recent congress trading data available."]
In Q4 2025, GXO posted revenue of $3.507 billion, up 7.91% YoY, which is a solid growth sign. However, profitability weakened sharply: net income dropped to $43 million, down 57.00% YoY, EPS fell 55.42% YoY to 0.37, and gross margin declined to 12.12. This suggests the company is still growing revenue, but earnings quality and margin performance were softer in the latest quarter.
Analyst sentiment has been mostly positive, but the trend has cooled slightly. In February, several firms raised targets and maintained Buy/Overweight/Outperform ratings, with targets generally in the high-$60s to low-$80s. On 2026-03-04, Goldman Sachs downgraded GXO to Neutral from Buy, citing reduced sector-relative upside after recent outperformance and slightly below-consensus EBITDA estimates. Wall Street is still broadly constructive, but the latest downgrade shows the pros side is becoming less aggressive while the bull case depends on earnings acceleration and margin expansion.
